Kornimate/medical-research-clean huggingface dataset:
helium:oxygen noninvasive positive pressure ventilation in patients exposed to sulfur mustard

Conditions: Bronchiolitis; Chronic Bronchitis

Summary: to assess the effect of heliox with noninvasive positive pressure ventilation to decrease dyspnea and improve physiologic and respiratory measures in patients with a previous exposure to sulfur mustard gas.


Eligibility criteria:
inclusion criteria: * exposure to sulfur mustard * worsening dyspnea during the last 10 days * respiratory rate of \>25/min * arterial ph\<7.35 * paco2 of \>50 mmhg * pao2 of \<50 mmhg exclusion criteria: * recent pneumothorax (\<1 month) * severe respiratory failure or hemodynamic instability with forthcoming intubation * fio2 of \<0.4 * impaired consciousness or absence of patient cooperation * facial lesions precluding nippv

Keywords: noninvasive ventilation helium oxygen sulfur mustard chronic bronchitis bronchiolitis
the effect of grinberg method (gm) intervention on low-back pain (lbp) and improving the quality of life

Conditions: Low Back Pain (LBP)

Summary: the purpose of the research is to check the efficiency of practicing the tools of the grinberg method (gm) in reducing low-back pain (lbp), reducing limitations in movement as a result of the pain, and improving the general quality of life. the hypothesis suggests that by learning to perceive pain differently, the level of pain will reduce and general well-being improved.

the research will include 140 patients, who attended the pain clinic due to chronic lbp. any change in the pharmacological regimen will be done with consult of the tending doctor and the change will be reported. tools and methods a patient, whom volunteers to take part in the research, will be invited to the ichilov pain clinic in order to fill-in questionnaires and sign an informed consent form. each participant in the experiment group will participate in a series of 6 sessions lasting 1 hour each, extending between 6 to 8 consecutive weeks, with one of the qualified gm practitioners partaking in the experiment. each participant will have all their sessions with the same gm practitioner throughout the experiment. immediately after the last session, the participants will fill-in the same questionnaires given at the beginning of the experiment. the non-gm intervention group will answer the questionnaires after 6-8 weeks of pharmacological treatment only. questionnaires: * general details and pain questionnaire * sf-mpq short form mcgill pain questionnaire, ronald melzack * rmdq - roland morris disability questionnaire * sf 36 - the short form health survey

Eligibility criteria:
inclusion criteria: * women and men, age range 18-65; patients of the ichilov pain clinic, who suffer from chronic lbp that lasts over 3 months and that appears several times a week. * lbp which is localized between the 12th rib and the inferior gluteal folds, with or without leg pain. the lbp may be non-specific, mechanical or radicular. exclusion criteria: * patients with malignancy and/or other life threatening conditions * diabetic patients * patients with fibromyalgia * pregnancy * paralysis * patients with obesity * patients that underwent organ transplantation * severe osteoporosis * patients that are scheduled to receive spinal cord injections during the research * patients that received less than 4 weeks before the research, other pain interventions than the standard of care treatment such as: alternative medicine (acupuncture, shiatsu, massage, reflexology, homeopathy etc'); physiotherapy, chiropractic, hydrotherapy, bio-feedback, osteopathy and others. * patients with severe mental disorders (such as schizophrenia, bipolar disorder, suicidal tendencies etc') * pain lasting less than 3 months

Keywords: low back pain
phase 1 study of multiple-dose pharmacokinetics of cenicriviroc in subjects with mild and moderate hepatic impairment

Conditions: Liver Insufficiency

Summary: to determine whether cvc exposures are altered in subjects with impaired hepatic function, compared to subjects with normal hepatic function. the results will help guide the clinical use of cvc in patients with hepatic impairment, determine the extent of pk changes, if any, and identify the potential need for dose adjustments of cvc in this population.


Eligibility criteria:
inclusion criteria: * males and non-pregnant, non-lactating females aged 18-65 * weight ≥ 50.0 kg * bmi 18.0 - 40.0 kg/m2 * able to participate, and willing to give written informed consent and to comply with the study restrictions * subjects with hepatic impairment will have stable liver disease (child pugh a or child pugh b) exclusion criteria: * pregnant or lactating women and male partners of women who are pregnant or lactating * uncontrolled treated or untreated hypertension (systolic blood pressure ≥ 160 mmhg and/or diastolic blood pressure ≥ 105 mmhg) * qtcf \> 450 msec for males and \> 470 msec for females at screening or day -1 * donation or loss of blood over 350 ml within 60 days prior to screening * any evidence of progressive liver disease within the last 4 weeks for subjects with hepatic impairment

Keywords: liver insufficiency hepatic impairment
effect of spiriva® on health-related quality of life in chronic obstructive pulmonary disease (copd) patients who stopped smoking during treatment.

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: post marketing surveillance to gain insights into the effects of therapy with spiriva® (tiotropium bromide) on health-related quality of life in copd patients who stopped smoking during treatment and to obtain safety data regarding adverse events.


Eligibility criteria:
inclusion criteria: * patients with copd * smoker at start exclusion criteria: * patients presenting with any general and specific contraindications listed in the patient information leaflet ('gebrauchsinformation') and the basic product information('fachinformation')
quality of care in as impulse study

Conditions: Aortic Valve Stenosis

Summary: the purpose of this study is to narrow the gap between patients being diagnosed with severe aortic stenosis and those being appropriately monitored and treated. for this purpose a prospective survey of current practice (3 months) will be conducted followed by a six month period of intervention during which a variety of quality improvements measures will be implemented. there will then be a 3 month follow-up period during which the legacy of this initiative will be monitored during which no intervention will be carried out.

all patients meeting pre-specified criteria (severe aortic stenosis whether with or without symptoms) will be collected. there will be three phases at each site observation a, intervention, observation b. observation a: in this phase, the nurse identifies cases with severe as and collects their data. baseline data for each patient will be collected and a follow-up will be done after three months for each patient to determine his/her outcome and the treatment that was decided on. there will also be an optional telephone follow-up to find out the patient's outcome. intervention: in this phase, the physician referring a patient for echocardiography will be notified of a finding of severe aortic stenosis: the nurse brings cases with severe as to the attention of the referring physician within a week (via phone, e-mail or letter) to make them aware of the diagnosis. baseline and follow-up data will be collected for each patient as before. moreover, more detailed data with regard to the patient's health status will be documented. observation b: same as observation phase a

Eligibility criteria:
inclusion criteria: * aortic valve area \< 1cm2 * indexed aortic valve area \<0.6 cm/m2 * maximum jet velocity \> 4.0 m/sec * mean transvalvular gradient \> 40 mmhg exclusion criteria: * non-severe aortic stenosis (as) * previous aortic valve replacement (avr)

Keywords: aortic valve stenosis echo tavi savr referral
cardiamp heart failure ii trial for patients with ischemic heart failure with reduced ejection fraction

Conditions: Ischemic Heart Failure

Summary: concentrated autologous bone marrow mononuclear cells (abm mnc) contain potentially therapeutic cell factors and past studies support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure when utilized as this study is designed. the purpose of the study is to determine the safety and efficacy of cardiamp cell therapy system in patients with ischemic heart failure. it is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded study comparing treatment with the cardiamp cell therapy system to a control procedure with diagnostic catheterization.

chronic heart failure is in need of new therapies. over the past few years, cardiovascular regenerative medicine using bone marrow derived cells has emerged as a new treatment strategy that could have tremendous benefit in treating heart failure and are well supported by recent meta analyses of early clinical data sets. concentrated autologous bone marrow mononuclear cells (abm mnc) are the subject of the current study as they are supported by more clinical data than any other cell type described, and contain all of the potentially therapeutic cell factors from studies of selected cells. study results demonstrate abm mnc to be safe, and, when delivered intramyocardially as intended in the current study, results consistently support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure. the purpose of the study is to determine the safety and efficacy of cardiamp cell therapy system in patients with ischemic heart failure. it is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded study comparing treatment with the cardiamp cell therapy system to a control procedure with diagnostic catheterization. the treatment group undergoes left ventricular catheterization and is treated with abm mnc using the cardiamp cell therapy system. the control group has a control procedure consisting of left ventricular diagnostic catheterization but no introduction of the helix transendocardial delivery catheter and no administration of abm mnc.

Eligibility criteria:
inclusion criteria: * new york heart association (nyha) class ii or iii * diagnosis of chronic ischemic left ventricular dysfunction secondary to myocardial infarction (mi) as described in the study protocol. * left ventricular ejection fraction \>20% and \<40% * on stable evidence-based medical and device therapy for ischemic etiology heart failure per the acc/aha heart failure guidelines, for at least three (3) months prior to randomization. * ntprobnp level of \>500 pg/ml * autologous cell analysis score consistent with study selection assessment exclusion criteria: * selected study criteria as defined in the study protocol indicating that patient is not an optimal candidate for cardiac catheterization or intramyocardial delivery of autologous bone marrow mononuclear cells.
mechanistic effects of health coaching to reduce chronic obstructive pulmonary disease (copd) hospitalizations

Conditions: COPD; Emphysema

Summary: the researchers are trying to explore the benefit of health coaching on patients with severe symptoms of copd.


Eligibility criteria:
inclusion criteria: men and women 40 years or older with a clinical diagnosis of copd with shortness of breath. exclusion: terminal illness, inability to communicate by phone

Keywords: health coaching
clinical trials with a local anesthetic lozenge for the treatment of chronic oral pain

Conditions: Chronic Pain

Summary: the aim of the project is to do a fase two trial, where the effect of a local anesthetic lozenge will be tested in regard to oral pain, dryness of the mouth, irregularity of taste as well as investigate a potential antiinflammatory effect in patients with burning mouth syndrome, sjögrens syndrome and lichen planus.


Eligibility criteria:
inclusion criteria: * diagnosed with burning mouth syndrome, sjögrens syndrome or lichen planus * all fertile women need to use save contraception * age between 18 and 75 years * able to speak, read and understand the danish language * must be informed orally and release a written consent and a signed authorization statement exclusion criteria: * pregnant or breastfeeding women * known allergy to bupivacaine or other local anesthetics of the amide type * active infection which requires antibiotic treatment * patients in immune suppressive treatment

Keywords: oral pain local anesthetic bupivacaine hydrochloride
exploring the knowledge, attitudes, behaviors and perceived barriers of hepatologists towards non-invasive hepatocellular carcinoma prediction models in hepatitis c patients who achieved sustained virological response following direct acting antivirals therapy

Conditions: Non-invasive Hepatocellular Carcinoma

Summary: this study aims to assess the knowledge, attitudes, and behaviors (kab) of hepatologists regarding different models used to predict hepatocellular carcinoma (hcc) in patients with chronic hepatitis c (hcv) who achieved sustained virological response (svr) after direct-acting antiviral (daa) therapy. the study will use a structured questionnaire targeting hepatologists globally to evaluate their familiarity with, confidence in, and clinical application of various predictive models. the primary outcome is the proportion of hepatologists who incorporate prediction models in clinical practice, while secondary outcomes include the level of knowledge about different models, perceived reliability, and barriers to their implementation the aim of the study 1) to evaluate the level of knowledge among hepatologists regarding existing hcc prediction models for post-svr hcv patients. 2) to assess hepatologists' attitudes toward the utility, reliability, and clinical value of these models. 3) to identify the extent to which hepatologists incorporate predictive models into their clinical decision-making. 4) to determine perceived barriers to the adoption of these models in clinical practice. 5) to explore the factors associated with poor adoption of these predictive models.


Eligibility criteria:
inclusion criteria: * hepatologists with at least one year of experience in managing hcv patients exclusion criteria: * non-hepatologists, general practitioners, or respondents who submit incomplete surveys
french travelers' knowledge of risk of acquiring esbl-pe

Conditions: Travel Medicine

Summary: since it is not routine practice in france to raise public awareness about the risk of acquiring multidrug resistant enterobacteriaceae (mre) during international travel, the investigators aimed to determine, among french travelers attending a consultation for travel medicine, patients level of knowledge about the risk of acquiring mre.

since it is not routine practice in france to raise public awareness about the risk of acquiring multidrug resistant enterobacteriaceae (mre) during international travel, the investigators aimed to assess, among persons attending a consultation for travel medicine and international vaccines, patients level of knowledge regarding the risk of acquiring mre, preventive behaviours and the need to inform health professionals that they had recently travelled if the patients require medical care after their return. a cross-sectional study was performed in the consultation for travel medicine and international vaccination in reims university hospital, france. all adult travellers who attended this consultation between january 2016 and may 2016 and who completed the questionnaire were included in the study. the questionnaire was completed before the planned travel. the travellers answered the questionnaires before seeing the physician.

Eligibility criteria:
inclusion criteria: * adult travellers who attended the consultation for travel medicine and international vaccination in reims university hospital * adult who completed the questionnaire

Keywords: multidrug-resistant enterobacteriaceae acquisition travellers' diarrhoea international travel
effectiveness of circulating dna for predicting the relapse and overall survival in nhl patients

Conditions: Diffuse Large B Cell Lymphoma; Peripheral T Cell Lymphoma

Summary: the purpose of this study is to evaluate the effectiveness of circulating dna from peripheral blood for predicting the prognosis and relapse in dlbcl and ptcl patients.

the investigators plan to prospectively involve 300 non-hodgkin lymphoma patients, including both diffuse large b cell lymphomas and peripheral t cell lymphomas without previous treatment from peking union medical college hospital. the following parameters were collected: age, sex, subtype, eastern cooperative oncology group (ecog) performance status (ps), ann arbor stage (i-iv), presence of b symptoms, number and type of involved sites, prognostic index including international prognostic index (ipi) for dlbcland pit for ptcl based on medical record review. all patients would have regular treatment and follow up in pumch. during the follow up, treatment response was evaluated by contrast enhanced computed tomography or pet-ct. the peripheral blood would be collected and circulating dna would be tested at the time of diagnosis, interim of treatment, end of treatment, 1 year follow-up, 1.5 year of follow-up, 2 year of follow up, 3 year of follow-up and disease progression or relapse. tcr/bcr domain would be sequenced by high-throughput sequencing.

Eligibility criteria:
inclusion criteria: 1. pathologically confirmed diffuse large b cell lymphoma (dlbcl nos, pcnsl, alk+ dlbcl, dlbcl/bl) or peripheral t cell lymphoma (aitl, alcl, ptcl nos, nk/t nasal type, eatl, hstl) 2. no treatment before 3. hcg(-) 4. 18 years old to 80 years old exclusion criteria: 1. other tumors 2. severe infections

Keywords: circulating dna diffuse large b cell lymphoma peripheral t-cell lymphoma prognosis
a clinical trial of yh1177 in patients with otitis media and otorrhea

Conditions: Otitis Media; Otorrhea

Summary: in patients with otitis media presenting with otoscopy-confirmed otorrhea who had tympanostomy tube insertion or tympanic perforation, to evaluate the safety, tolerability, and the proportion of patients with cessation of otorrhea after ear-drop administration of yh1177 or yh1177-d for 14 days and therefore to determine the optimal clinical dose.

patients with otitis media presenting with otoscopy-confirmed otorrhea who had tympanostomy tube insertion or tympanic perforation. screening should be completed within 7 days prior to randomization. patients with otitis media presenting with otoscopy-confirmed otorrhea who had tympanostomy tube insertion or tympanic perforation at randomization visit will be randomized in one of the defined groups.

Eligibility criteria:
inclusion criteria: * signed written informed consent a detailed explanation about the study, including the study purpose and procedures and drug properties, had been provided, and the patient gave voluntary written informed consent. * target population patients with otitis media presenting with otorrhea, as evidenced by otoscopy, who had tympanostomy tube insertion or tympanic perforation * sex and age male or female patients 19 years of age or older at screening women of childbearing potential (wocbp) must have 'negative' pregnancy test at screening, and use an acceptable method of contraception throughout the study. exclusion criteria: * excluded disease 1. patients diagnosed with otitis media with cholesteatoma, otitis media with effusion or otitis externa at screening 2. patients who had a otologic surgery within 1 year prior to screening (except for tympanostomy tube insertion) 3. subjects who previously had cholesteatoma or mastoid surgery * medical history and concurrent disease 1. patients with complication of labyrinthine fistula at screening 2. patients with clinically significant medical or mental illness. 3. patients with infectious disease requiring the use of systemic antimicrobial therapy * physical and laboratory test results a)clinically significant finding based on the principal investigator/investigator's opinion. * allergies and adverse drug reactions 1. known drug allergy (e.g., a history of anaphylaxis or hepatotoxicity) 2. history of hypersensitivity to penicillins or -lactamase inhibitors. 3. history of serious skin reaction such as stevens-johnson syndrome or toxic epidermal necrosis * prohibited therapies and/or medication 1. patients undergoing a ventilation tube insertion on the day of screening 2. patients with ventilation tube containing silver oxide or silver salt (e.g., t-type tube) * reproductive status, women only a)woman of childbearing potential (wocbp) who is unable, or unwilling to use an acceptable method of contraception during the study * other exclusion criteria 1. history of alcohol or drug abuse/addiction within the last 1 year prior to the study entry 2. patient who, in the investigator's opinion, is not suitable for the study for any reason (e.g., ecg or hepatitis test results at screening)
disclosure intervention for people in recovery from opioid use disorder

Conditions: Opioid-use Disorder

Summary: many people with substance use disorders struggle with decisions regarding whether to disclose to others that they have a history of substance use and/or are in recovery. yet, these decisions are important because disclosures can lead to reactions from others that harm or help recovery. for example, stigmatizing responses can harm the mental health of people in recovery whereas supportive responses can strengthen people's commitment to their sobriety. we have developed a brief intervention to help people decide whether and how to tell others about their recovery as well as build skills for disclosure. the purpose of this study is to pilot test this intervention and test its acceptability and feasibility as well as determine if it shows preliminary signs of efficacy in comparison to a control condition. we hypothesize that: (1) participants exposed to the intervention condition will agree that the intervention is acceptable and feasible, and (2) participants in the intervention condition will report higher quality decision making in comparison to participants in the control condition.

data will be collected from participants at two time points, spaced one month apart. all participants will be recruited from the waiting room at a local treatment center. the research assistant will screen interested individuals for eligibility in person and schedule study appointments, which may be coordinated with treatment appointments. all study screening and appointments will be conducted in private spaces at the treatment center. at the first study appointment, the research assistant will introduce the study, check for questions, and obtain consent for the study procedures, medical record review, and follow up procedures. participants will be randomly assigned to receive either the disclosure intervention or a control intervention (i.e., an evidence-based mindfulness intervention). following the intervention, participants will complete measures of acceptability, feasibility, and decision quality. at the second study appointment, participants will again be asked to respond to survey and interview questions designed to further evaluate the preliminary efficacy of the intervention. in particular, we will investigate whether participants who completed our disclosure intervention report better relationship outcomes than participants who completed the control condition.

Eligibility criteria:
inclusion criteria: * 18 years or older * currently receiving outpatient treatment at the recruitment site * are considering disclosing their recovery status to at least one person in the next month * have access to a phone that can receive text messages and phone calls exclusion criteria: * current diagnosis of severe mental illness

Keywords: disclosure social support stigma patient decision aid